BDBM160009 US10017516, Compound 38::US9682983, 38
SMILES N#Cc1cc(ccc1N1CCNCC1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12
InChI Key InChIKey=QDSMDFVMOMUBDR-UHFFFAOYSA-N
Data 10 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 10 hits for monomerid = 160009
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 110nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 47nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 1.59E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 1.41E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 2.15E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 110nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 47nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 1.59E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.41E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women'S Hospital
US Patent
The Brigham and Women'S Hospital
US Patent
Affinity DataIC50: 2.15E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair